CTBP1 and neoplasm: The ability of the 4-Cl-HIPP/GMX1778 combination to effectively limit PDAC cell growth in vitro and tumor growth in vivo thus supports our hypothesis that combining CtBP inhibition with NAD depletion could be an effective and well-tolerated therapeutic strategy in human PDAC.